Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,068 recruiting studies in this area right now.
By phase
- Not applicable3,005
- Phase 21,062
- Phase 1794
- Phase 1/Phase 2441
- Phase 3435
- Phase 4233
- Phase 2/Phase 398
Top conditions
- Multiple Sclerosis330
- Multiple Myeloma328
- Asthma194
- Lymphoma179
- Rheumatoid Arthritis131
- Type 1 Diabetes131
- Atopic Dermatitis123
- Systemic Lupus Erythematosus121
- Acute Lymphoblastic Leukemia118
- HIV Infections106
- Chronic Lymphocytic Leukemia96
- Autoimmune Diseases79
- Follicular Lymphoma70
- Rheumatoid Arthritis (RA)68
- Hodgkin Lymphoma64
- Diabetes Mellitus, Type 163
- Leukemia63
- Type 1 Diabetes Mellitus63
Leading sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)97
- Institute of Hematology & Blood Diseases Hospital, China85
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris65
- AstraZeneca64
- M.D. Anderson Cancer Center58
- Novartis Pharmaceuticals58
- Mayo Clinic50
- City of Hope Medical Center49
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California498
- Maryland198
- Alabama179
- Florida152
- Arizona150
- Massachusetts118
- New York116
- Texas112
- Illinois82
- Colorado81
Recruiting studies6,068 total
- NCT04704323RecruitingPhase 1
CAP-100 drug study for hard-to-treat CLL after prior treatments
This early-phase (Phase 1) study tests CAP-100 in adults with CLL or SLL that has come back or did not respond to at least two previous treatments. The goal is to see how the drug works and whether it is safe enough to keep studying.
Boston, MassachusettsAges 18 years+ - NCT06171412Recruiting
Peer mentoring to help Black and Latinx people with type 1 diabetes use CGM more
This study tests whether support from a peer mentor can help Black and Latinx adults with type 1 diabetes who currently use a continuous glucose monitor (CGM) less than half the time to use it more regularly. You'll join remote video sessions with a mentor who has experience with diabetes.
New Haven, ConnecticutAges 13–21 - NCT06347939Recruiting
Lung lymph node biopsy study
This study tests a new way to take tissue samples from swollen lymph nodes in the chest using a thin tube passed through the mouth. It aims to see if this method is safe and effective.
LundAges 18 years+ - NCT06796686RecruitingPhase 1
HIV vaccine safety and immune response study for healthy adults
This trial tests a new two-part HIV vaccine regimen in healthy adults without HIV. The goal is to see if it is safe and produces an immune response that could help prevent HIV.
San Francisco, CaliforniaAges 18–55 - NCT06795815Recruiting
Using the Go Wish Game for Future Care Planning
This trial tests a game called 'Go Wish' that helps people with serious cancer think about and talk about their future care wishes. It's designed to help you plan ahead with your care team.
Reggio EmiliaAges 18–99 - NCT06797518RecruitingPhase 2
Testing iptacopan for IgA nephropathy kidney changes
This study tests if adding iptacopan to standard care can improve kidney health in adults with IgA nephropathy. You may qualify if you have a kidney biopsy confirming IgA nephropathy and your kidney function is stable enough.
Birmingham, AlabamaAges 18–99 - NCT06795893Recruiting
Anifrolumab pregnancy outcomes study
This study collects information on pregnancy outcomes in women who took the drug anifrolumab during pregnancy or within 16 weeks before conception. It helps researchers understand how the drug may affect pregnancy and the baby.
SödertäljeAges Any age - NCT06798298Recruiting
Long-term safety study of gene modified T cell treatment
This study is a long-term safety check for people who have already received a gene modified T cell treatment in a previous study sponsored by 2seventy bio or Regeneron Pharmaceuticals. The goal is to monitor your health for years after that treatment to see how well it works and if any side effects appear over time.
Nashville, TennesseeAges 18 years+ - NCT06796504Recruiting
Nerve stimulation for relapsing-remitting multiple sclerosis
This trial tests a device that stimulates a nerve in the neck, which may help repair the protective coating around nerves in the brain and spinal cord. It is for people with relapsing-remitting MS who are stable on their current medication and have some vision problems due to MS.
Irvine, CaliforniaAges 22–60 - NCT06801119RecruitingPhase 1
HN2301 for autoimmune diseases study
This trial tests a new mRNA treatment called HN2301 for people with autoimmune diseases like lupus, scleroderma, or rheumatoid arthritis. It aims to see if the treatment is safe and helps control the disease.
Hefei, AnhuiAges 18–69 - NCT06801002RecruitingPhase 1
Safety trial of JBZ-001 for advanced cancers
This trial tests a new drug, JBZ-001, to see how safe it is for people with advanced solid tumors or certain types of lymphoma that have not improved with standard treatments. It's a first-in-human study, so participants will help doctors learn about the drug's side effects and the right dose.
Columbus, OhioAges 18 years+ - NCT06798012RecruitingPhase 2
TAK-411 for adults with CIDP
This study tests a new investigational drug called TAK-411 for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). It is for people who have already responded to immunoglobulin therapy and are on a stable dose.
La Jolla, CaliforniaAges 18 years+ - NCT06795230Recruiting
Arm exercise with blood flow cuffs for MS
This study tests a type of arm exercise that uses a blood pressure cuff to limit blood flow, aiming to improve arm function in people with multiple sclerosis. It may help if you have some arm weakness but no recent relapses or blood clotting issues.
Leganés, MadridAges 18 years+ - NCT06792825RecruitingPhase 2
Tafasitamab with lenalidomide and rituximab for new lymphoma
This trial tests a combination of three drugs (tafasitamab, lenalidomide, and rituximab) for people with newly diagnosed follicular or marginal zone lymphoma who have not had treatment before. The goal is to see if this combination works well and is safe.
Minneapolis, MinnesotaAges 18 years+ - NCT06793449RecruitingPhase 2
BCMA CAR-T vs. stem cell transplant for multiple myeloma
This trial tests whether a newer immune treatment (BCMA CAR-T) works better than a stem cell transplant for people with multiple myeloma who are able to have a transplant. Both treatments aim to kill myeloma cells, but CAR-T uses your own engineered immune cells.
TianjinAges 18–70 - NCT06801821Recruiting
Stigma study on skin conditions
This study looks at how people view those with certain skin conditions. It aims to understand stigma, which may help improve awareness and support.
Roma, ItaliaAges 18 years+ - NCT06803446Recruiting
How does daily rhythm affect blood sugar during exercise in type 1 diabetes?
This study looks at how the time of day affects blood sugar control during moderate exercise and intense activity in teens with type 1 diabetes. It may help find the best times for exercise to manage glucose better.
Loos, NordAges 10–16 - NCT06795126Enrolling by invitation
Virtual reality for pain and anxiety in kids getting IVs
This study tests if a virtual reality game called Little NIRVANA can help reduce pain and anxiety in children getting an IV. It's for kids ages 2 to 8 in the emergency department.
Columbus, OhioAges 2–8 - NCT06796998RecruitingPhase 2
Epcoritamab for newly diagnosed marginal zone lymphoma
This trial tests a new immunotherapy drug, epcoritamab, for people who have been recently diagnosed with marginal zone lymphoma (MZL) and haven't had treatment yet. The goal is to see if the drug can shrink tumors or control the disease.
Miami, FloridaAges 18 years+ - NCT06793189RecruitingPhase 2
Risk-Adapted Targeted Therapy for Untreated MZL
This trial tests a personalized treatment plan for people with newly diagnosed marginal zone lymphoma (MZL). The treatment is based on a risk score and aims to be more targeted than standard chemotherapy.
Shanghai, ChinaAges 18 years+ - NCT06799195RecruitingPhase 2
Better GVHD prevention after stem cell transplant
This trial tests a new approach to prevent graft-versus-host disease (GVHD) after a stem cell transplant from a matched donor. It is for people aged 60 or older with a blood cancer or serious blood disorder who are getting a reduced-intensity conditioning regimen.
Omaha, NebraskaAges 60 years+ - NCT06792994Recruiting
CLL treatment sequence study for patients in GCLLSG trials
This observational study looks at the order of treatments given to people with chronic lymphocytic leukemia (CLL) who took part in certain first-line studies run by the German CLL Study Group. It aims to learn how different treatment sequences affect overall survival over time.
CologneAges 18–99 - NCT06799026RecruitingPhase 1
Vaccine plus elranatamab for advanced multiple myeloma
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) mixed with myeloma cells, given together with a drug called elranatamab. It is for people with multiple myeloma that has not responded to at least three prior treatments.
Boston, MassachusettsAges 18 years+ - NCT06793163Recruiting
Finding causes of severe allergic reactions during surgery
This study looks at what causes severe allergic reactions during surgery. It helps doctors find out which medicine or substance triggered the reaction, so they can avoid it in the future.
Beijing, Beijing MunicipalityAges 2 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,068 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,217 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.